Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Net Margin (2016 - 2025)

IGC Pharma has reported Net Margin over the past 16 years, most recently at 953.4% for Q3 2025.

  • Quarterly Net Margin fell 53666.0% to 953.4% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 582.82% through Sep 2025, up 47965.0% year-over-year, with the annual reading at 560.27% for FY2025, 40628.0% up from the prior year.
  • Net Margin was 953.4% for Q3 2025 at IGC Pharma, down from 487.5% in the prior quarter.
  • Over five years, Net Margin peaked at 362.73% in Q1 2025 and troughed at 7757.14% in Q3 2021.
  • The 5-year median for Net Margin is 977.97% (2024), against an average of 1847.1%.
  • The largest YoY upside for Net Margin was 723512bps in 2021 against a maximum downside of -643154bps in 2021.
  • A 5-year view of Net Margin shows it stood at 1676.76% in 2021, then surged by 60bps to 677.41% in 2022, then tumbled by -304bps to 2739.71% in 2023, then soared by 74bps to 711.67% in 2024, then plummeted by -34bps to 953.4% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Net Margin are 953.4% (Q3 2025), 487.5% (Q2 2025), and 362.73% (Q1 2025).